small molecule

OFEV

NINTEDANIB ESYLATE

Loss of exclusivityDecember 2029latest FDA-listed patent expiry

CompanyBoehringer Ingelheim →View the full company profile on CliffBio

Drug detail

Brand name	OFEV
Active ingredient	NINTEDANIB ESYLATE
Strength	EQ 150MG BASE
Dosage form	CAPSULE
Route	ORAL
Modality	Small molecule
FDA approval	October 2014
Marketing status	RX

Listed patents

Patent	Expires	Type
9907756*PED	December 2029	—
10105323*PED	December 2029	—
9907756	June 2029	product
10105323	June 2029	product
10154990*PED	July 2026	—
6762180*PED	April 2026	—
10154990	January 2026	use U-2620
6762180	October 2025	substance, product

Regulatory exclusivity

Code	Expires
PED	March 2027
ODE-261	September 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Boehringer Ingelheim